@masterash
Yes, more of BLs shares come out of Escrow in Juky, however we will be unable to sell them as the stock will be in a "restricted window"
If everything's on track, the FDA submission would have been made in 1H with a decision in Q3...
There is no chance in hell he would be able to legally sell his shares during the FDA's processing window - the board wouldn't approve & ASIC would also have concerns.
Thus - his window would open after the FDA decision... In which case he'd probably be getting over $1 each in any event IMO
Finally, for all those who doubted the "legitimacy" of BLs claim to satisfy a tax liability due, hence selling all those months ago - yesterday's Half Yearly report should help the understanding of this.
The company incurred $5.5m in "Share Based Payments" expense due to the issue of options to directors & key staff... This expense is also recognized as income for whomever received it - BL would have received a significant amount of these...
Note that BL also received Share Based Payments from his other directorships too... Look at Alcidion (ALC) his receipt was c. $700k alone on that one.
Hope that puts to bed any lingering worries about the past & we can embrace THE MONTH OF MARCH!!
This is it... It all comes together this month!
